New treatment using bevacizumab and novel diagnostic method for radiation necrosis
Project/Area Number |
23592145
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Cerebral neurosurgery
|
Research Institution | Osaka Medical College |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
KAWABATA Shinji 大阪医科大学, 医学部脳神経外科, 講師 (20340549)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 放射線壊死 / 血管新生 / ベバシズマブ / アミノ酸PET / 炎症 / 血管内皮増殖因子 / radiation necrosis / VEGF / PDGF / bevacizumab / PET / ベバシズマブ |
Research Abstract |
There was a significant correlation between effectiveness of bevacizumab and uptake of F-BPA-PET in radiation necrosis. Reduction of perilesional edema by bevacizumab contributed to improvement of performance status in patients with radiation necrosis. In pathological study, reactive astrocytes and monocytes played important roles, expressing HIF-1alfa, VEGF, CXCR4, CXCL12, PDGR, and PDGF-R. We have still tried to establish experimental radiation necrosis in rats.
|
Report
(4 results)
Research Products
(49 results)
-
-
-
-
-
[Journal Article] Inflammation as well as angiogenesis may participate in the pathophysiology of brain radiation necrosis.2014
Author(s)
Yoritsune E, Furuse M, Kuwabara H, Miyata T, Nonoguchi N, Kawabata S, Hayasaki H, Kuroiwa T, Ono K, Shibayama Y, Miyatake SI
-
Journal Title
J Radiate Res
Volume: in press
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-